Eli Lilly spun off Elanco and refocused on medicines before the GLP-1 boom

Eli Lilly owned Elanco, a large animal-health business, while trying to rebuild around higher-value human medicines. In September 2018, Lilly transferred substantially all animal-health operations to Elanco and Elanco completed its IPO.

The separation gave Lilly cash and a cleaner strategic profile. Elanco's 2018 10-K said the IPO sold 72.3 million shares at $24 and that Lilly retained 80.2% before the later exchange offer.

By 2023, Lilly's growth story was concentrated in human medicines. Revenue rose 20% to $34.12 billion, driven by products including Mounjaro; Mounjaro alone generated $5.16 billion of 2023 revenue.

Lilly's 2023 revenue rose 20% to $34.12B; Mounjaro produced $5.16B of revenue.

The Elanco split moved animal health out of Lilly's capital-allocation debate.

A focused human-medicines portfolio made it easier to fund and explain large diabetes, obesity, oncology, and immunology bets.

The timing left Lilly cleaner before tirzepatide became one of pharma's largest growth platforms.

A conglomerate-like portfolio can hide the business that deserves the capital; separation clarifies the bet.

Lilly fully separated Elanco in 2019 through an exchange offer. The company later became defined by human drug launches, especially GLP-1 products Mounjaro and Zepbound, while Elanco operated as an independent animal-health company.